Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia

Elmars Rancans (Coresponding Author), Zsófia Borbála Dombi, Ágota Barabássy

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
1 Downloads (Pure)

Abstract

Although the optimal dosing of an antipsychotic medication is known to be essential in the long-term management of schizophrenia, in case of novel drugs such as cariprazine, determining the right dosing strategy is not that simple. Without decades of experience with a particular compound, evidence regarding dosing and titration comes primarily from double-blind, placebo controlled clinical trials that are not necessarily mirroring the real-life experiences of doctors. Via summarizing data from both clinical data (n = 3275) and real-world evidence (observational study n = 116, case studies n = 29), this perspective paper aims to shed a light on the appropriate dosing strategies of cariprazine from treatment initiation through switching strategies to concomitant medications.

Original languageEnglish
Article number770234
Pages (from-to)770234
JournalFrontiers in Psychiatry
Volume12
DOIs
Publication statusPublished - 5 Jan 2022

Keywords*

  • antipsychotic
  • cariprazine
  • dosing
  • psychopharmacotherapy
  • schizophrenia

Field of Science*

  • 3.2 Clinical medicine

Publication Type*

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia'. Together they form a unique fingerprint.

Cite this